Patients' Experience of Living With and Managing **Presbyopia: A Systematic Literature Review**


RESULTS

Zach Baldwin, PharmD candidate,¹ Joanna Campbell, PhD,² Elaheh Shirneshan, PhD² ¹University of Washington School of Pharmacy, Seattle, WA, USA; ²Allergan, an AbbVie company, Irvine, CA

Table 1. Population, Intervention, Comparator, Outcomes, Timing, Setting, Study Design (PICOTS)

Dimension	Inclusion/Excluson Criteria
Population	 Inclusions: 35 or older; OR Presbyopia diagnosis with or without myopia, hyperopia, or astigmatism Exclusions: Glaucoma, acute iritis, visually significant cataracts, severe dry eye disease, corneal abnormalities (eg, corneal scars, keratoconus, Fuch's endothelial dystrophy, guttata, edema) in either eye that are likely to interfere with visual acuity
Intervention	 Inclusions: Spectacles (reading/bifocal/trifocal/progressive lenses); AND/OR Contact lenses (monovision/ bifocal/ multifocal); AND/OR Surgery (laser refractive surgery [laser in situ keratomileusis (LASIK) surface ablations, Intracor], intracoular lens surgery [any], thermokeratoplasty, scleral relaxation, and corneal inlays [KAMRA]); AND/OR None (ie, natural history)
Comparator Outcomes	 Not applicable Studies reporting at least one of the following: Patient experience of living with presbyopia Limitations of current treatment options and unmet need from patient's perspectives Patient experience with current treatment options Unmet needs from patients' perspectives Patient preferences for a presbyopia treatment option
Timing Geographic setting	1990 to present Global
Study design	 Randomized controlled trials Observational studies (prospective/retrospective/cohorts/cross-sectional) Economic evaluations Natural history studies Systematic literature reviews, meta-analyses, or network meta-analyses of these studies Non-systematic or narrative review Patient survey/interview, focus group Exclusion: Case series, case study

Figure 1. PRISMA Flowchart S



þ Table 2. Study Characteristics, Subset for Visual Ease³ (Cont'

Author, Year; Study Design	Region	Intervention Category	Inclusion/Exclusion	N (Patients)	Outcome(s)
Bakaraju et al. 2018 ⁶ ; Randomized CCT	Australia	Contacts	Incl: VA, near addition	43	Limitations of Current Treatment Option
Chu et al. 2009 ⁷ ; Cross-sectional	Australia	SpectaclesContacts	 Incl: age, driver's license Excl: cataracts, glaucoma, AMD 	255	 Impact of Uncorrected Presbyopia Limitations of Current Treatment Option
Diec et al. 2017 ⁸ ; CCT	Australia	Contacts	 Incl: VA, near addition Excl: ocular surgery, ocular conditions 	55	Limitations of Current Treatment Option
Du Toit et al. 2001 ⁹ ; Randomized CCT	Canada	Contacts	 Incl: established presbyopes Excl: ocular disease, general health conditions 	150	Limitations of Current Treatment Option
Erickson et al. 1990 ¹⁰ ; Systematic review	US	Contacts	Not applicable	N/A	Limitations of Current Treatment Option
Fylan et al. 2005 ¹¹ ; Cross-sectional	UK	 Spectacles 	Incl: established presbyopes	158	 Limitations of Current Treatment Option Psychosocial Burden of Spectacles
Fylan et al. 2005b ¹² ; Cross-sectional	UK	 Spectacles 	 Incl: established presbyopes 	158	 Limitations of Current Treatment Option Psychosocial Burden of Spectacles
Goldberg et al. 2001 ¹³ ; Cross-sectional	US	 Surgery 	 Incl: age, LASIK recipient Excl: amblyopia, disabilities affecting walking, surgery, IOL implant 	233	Limitations of Current Treatment Option
Goldberg et al. 2003 ¹⁴ ; Cross-sectional	US	Surgery	Incl: age, LASIK recipient	388	Limitations of Current Treatment Option
ldowu et al. 2016 ¹⁵ ; Cross-sectional	Nigeria	 Spectacles 	Incl: VA, near addition	488	 Limitations of Current Treatment Option Psychosocial Burden of Spectacles
Kidd Man et al. 2016 ¹⁶ ; Cross-sectional	Singapore	 Spectacles 	Incl: VA, near addition	7890	 Impact of Uncorrected Presbyopia
Koduah et al. 2019 ¹⁷ ; Cross-sectional	Ghana	 Spectacles 	Incl: VA, near addition	136	 Impact of Uncorrected Presbyopia Limitations of Current Treatment Option Psychosocial Burden of Spectacles
₋aviers et al. 2010 ¹⁸ ; Cross-sectional	Zanzibar	 Spectacles 	Incl: VA, near addition	381 (340 presbyopia)	 Impact of Uncorrected Presbyopia
//cDonnell et al. 2003 ¹⁹ ; Prospective cohort	US	SpectaclesContactsSurgery	 Incl: age, established presbyopes, VA, near addition Excl: chronic ocular disease, diabetes, cognitive/neurologic impairment 	637	Limitations of Current Treatment Option Psychosocial Burden of Spectacles
Patel et al. 2010 ²⁰ ; Prospective cohort	Tanzania	 Spectacles 	 Incl: age, VA, near addition 	866	 Impact of Uncorrected Presbyopia
Reddy et al. 2018 ²¹ ; RCT	India	 Spectacles 	 Incl: VA, near addition Excl: already have readers 	751	 Impact of Uncorrected Presbyopia
Richdale et al. 2006 ²² ; Randomized CCT	US	 Spectacles Contacts 	 Incl: VA, near addition Excl: ocular disease, prior experience 	38	 Limitations of Current Treatment Optior Psychosocial Burden of Spectacles
Rueff et al. 2016 ²³ ; Cross-sectional	US	Contacts	Inclusion: age	496	Limitations of Current Treatment Option
Sha et al. 2016 ²⁴ ; Randomized CCT	Australia	Contacts	 Incl: age, VA, near addition Excl: surgery, contraindication 	Mild impairment: 20 Moderate & severe impairment: 22	Limitations of Current Treatment Option
Sha et al. 2018a ²⁵ ; Randomized CCT	Australia	Contacts	 Incl: VA, near addition, established wearers 	57	Limitations of Current Treatment Option
Sha et al. 2018b ²⁶ ; CCT	Australia	Contacts	 Incl: near addition, VA, refractive error Excl: ocular/systemic conditions preventing safe wear, eye surgery, corneal surgery 	85	Limitations of Current Treatment Option
Uche et al. 2014 ²⁷ ; Cross-sectional	Nigeria	 Spectacles 	 Inclusion: age, visual acuity, near addition Excl: VA (severe) 	585 (371 presbyopia)	 Impact of Uncorrected Presbyopia Limitations of Current Treatment Option
Noods et al. 2009 ²⁸ ; Randomized CCT	Canada	Contacts	 Incl: age, near vision difficulties, no correction experience 	25	Limitations of Current Treatment Option
Noods et al. 2015 ²⁹ ; Randomized CCT	Canada	Contacts	 Incl: age, near addition, VA, good fit with lenses Excl: systemic health/medication 	50	Limitations of Current Treatment Option
Wright et al 1999 ³⁰ ; Retrospective cohort	US	Surgery	Incl: 1D or more of anisometropia in intervention, 0.5D or less in control	Myope: 21 Emmetrope: 19	Limitations of Current Treatment Option
Wubben et al. 2014 ³¹ ; Prospective cohort	Philippines	 Spectacles 	Incl: age, VA, near addition	142	 Impact of Uncorrected Presbyopia Limitations of Current Treatment Optior
Zeri et al. 2019 ³² ; Cross-sectional	Italy	Contacts	 Incl: presbyopic patients who attempted either successfully or unsuccessfully to use contacts 	237	Limitations of Current Treatment Option

conducted

SODS

Σ

- Search Methods and Sources A systematic literature review of PubMed and Embase was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
- quidelines² A hand search of reference lists of included relevant articles was also

Eligibility Criteria, Study Selection, and Data Extraction

- Studies were selected according to the predetermined inclusion and exclusion criteria (**Table 1**)
- Study characteristics, interventions, and subjective outcomes were independently extracted from included studies (Figure 1)

Quality Appraisal Tools

- Cochrane Risk of Bias Tool for Randomized Controlled Trials³
- Newcastle Ottawa Scale for cohort⁴ and a modified version for cross-sectional studies⁵

CTION Background

NDO

ř

- Presbyopia is a progressive condition that reduces the eye's ability to focus on near objects with increasing age
- It is highly prevalent, affecting an estimated 1.8 billion people worldwide¹
- The currently available treatment options include spectacles (reader. bifocal. progressive), contact lenses (monovision, multifocal), and surgery (laser refractive surgery, intraocular lenses, corneal inlay)

Objectives

- The primary objective was to summarize existing literature surrounding the burden of uncorrected presbyopia and limitations of current treatment options from the patients' perspective
- The secondary objective was to assess the psychosocial burden of spectacles, as reported by individuals with presbyopia, for near-vision correction





Limited published literature on patient experience with presbyopia, specifically with spectacle usage



Uncorrected presbyopia significantly impacts activities of daily life



Individuals with presbyopia have reported distinct limitations and/or drawbacks to each treatment option, resulting in unmet needs



Appearance is a key concern associated with use of spectacles for presbyopia correction

Outcome(s)

Ŷ

5

Ο

Primary Objective: Burden of Living With and Managing Presbyopia From Patients' Perspective

- All 27 studies had outcomes that addressed the primary objective (Table 2)
- Our primary objective was further broken down into 2 categories: (1) Impact of Uncorrected Presbyopia, and (2) Limitations of Current Treatment Options

Impact of Uncorrected Presbyopia (n=8)

- Individuals with uncorrected presbyopia reported significant impact to activities of daily life:
- Highest impact was reported on activities requiring sharp near-vision, such as reading and writing - Less impact was reported on intermediate- and distance-vision activities, such as watching television, reading street signs, recognizing people's faces, seeing stairs, and cooking
- Studies comparing subjective outcomes, with and without near-vision correction, reported significant improvement in overall patient experience and patient-reported outcomes when a form of presbyopia correction was used, such as higher satisfaction with near-vision, less role limitation, and less reliance on others for activities of daily living

Limitations of Current Treatment Options (n=23)

- Spectacles: frequently had higher dependence ratings and lower expectations for visual outcomes
- Bifocal glasses had issues with change of focus
- Progressive glasses had distorted peripheral vision
- In underdeveloped communities, reasons for not having spectacles were driven by cost or prevention of successful acquisition, such as being lost or stolen
- Contact lenses: ocular symptoms such as ghosting, dryness, discomfort, blurred vision, and glare were frequently reported
- Clarity of vision scores decreased at decreasing distances; the issue of impacted near vision isn't sufficiently met
- Overall nighttime vision was rated worse than daytime vision, with subjective driving scores significantly lower at night
- Surgery: ocular symptoms such as glares, haloes, and ghosting were frequently reported - Monovision LASIK patients reported still needing reading glasses occasionally

Secondary Objective: Psychosocial Burden of Spectacles

· Six studies nested within Limitations of Current Treatment Options had results that touched upon the psychosocial burden attributable to spectacles

Psychosocial Burden of Spectacles (n=6)

- · Concerns about aesthetic appearance was the most frequently reported psychosocial issue with spectacles (Figure 2)
- Other cited concerns included worry about others' perception, not wishing to change frames or lenses, and feeling older

Figure 2. Word Cloud. Generated from word and phrase frequency of patient-response surveys	price friends changing by the
	decisions difficulty best-quality

THANK YOU to all the mentors who helped me conduct this systematic literature review!

This study was sponsored by Allergan plc, Dublin, Ireland (now AbbVie Inc., North Chicago, Illinois, USA). All authors met ICMJE authorship criteria. Neither honoraria nor payments were made for authorship. Financial arrangements of the authors with companies whose products may be related to the present report are listed as hose products may be related to the present report are listed, as declared by the authors.

Joanna Campbell and Elaheh Shirneshan are full-time employees of AbbVie Inc. Zach Baldwin was an intern through the AMCP Foundation and AbbVie Inc. and functioned as an external author after the internship was completed





	Fricke TR, et al. Ophthalmology. 2018;125:1492-1499.	17. Koduah C, et al. Int J
	Moher D, et al. PloS Med. 2009;6:e1000097.	18. Laviers H, et al. Invesi
	Sterne JAC, et al. BMJ. 2019;366:14898.	19. McDonnell P, et al. An
	Stang A. Eur J Epidemiol. 2010;25:603-605.	20. Patel I, et al. Br J Oph
	Modesti PA, et al. PLoS ONE. 2016;25:e0147601.	21. Reddy PA, et al. Lanc
	Bakaraju R, et al. J Optometry. 2018;11:21–32.	22. Richdale K, et al. Opto
	Chu B, et al. Eye Contact Lens. 2009;35:133–143.	23. Rueff E, et al. Optom
8.	Deic J, et al. Eye Contact Lens. 2017;43:340-345.	24. Sha J, et al. Arq Bras
9.	Du Toit R, et al. Optom Vis Sci. 2001;78:455-462.	25. Sha J, et al. Optom Vi
10.	Erickson P, et al. Optom Vis Sci. 1990;67:22-28.	26. Sha J, et al. Eye Cont
	Fylan F, et al. Health Expert. 2005;8:18–25.	27. Uche J, et al. Rural Re
	Fylan F, et al. Patient Educ Couns. 2005;56:291–295.	28. Woods J, et al. Eye C
13.	Goldberg DB, et al. J Cataract Refract Surg. 2001;27:1449-1455.	29. Woods J, et al. Optom
14.	Goldberg DB, et al. J Cataract Refract Surg. 2003;29:1695-1701.	30. Wright KW, et al. J Ca
15.	Idowu O, et al. Niger Postgrad Med J. 2016;23:132-136.	31. Wubben T, et al. BMC

Presented at Academy of Managed Care Pharmacy (AMCP) Nexus 2020 Virtual, October 19-23, 2020